CKM | Creatine kinase, muscle | Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CLCN2 | Chloride channel, voltage-sensitive 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
COMT | Catechol-O-methyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPS1 | Carbamoyl-phosphate synthase 1, mitochondrial | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPT2 | Carnitine palmitoyltransferase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CYP11B1 | Cytochrome P450, family 11, subfamily B, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CYP17A1 | Cytochrome P450, family 17, subfamily A, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
CYP19A1 | Cytochrome P450, family 19, subfamily A, polypeptide 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DBH | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
DDC | Dopa decarboxylase (aromatic L-amino acid decarboxylase) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DNMT1 | DNA (cytosine-5-)-methyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
DPEP1 | Dipeptidase 1 (renal) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
DPP4 | Dipeptidyl-peptidase 4 | CD markers Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
DRD5 | Dopamine receptor D5 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
EPHA2 | EPH receptor A2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ESR1 | Estrogen receptor 1 | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
F2 | Coagulation factor II (thrombin) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
FASN | Fatty acid synthase | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
FCER1A | Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
FCER1G | Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
FDPS | Farnesyl diphosphate synthase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
FGF1 | Fibroblast growth factor 1 (acidic) | Cancer-related genes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Group enriched |
FGF2 | Fibroblast growth factor 2 (basic) | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Mixed |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FLT1 | Fms-related tyrosine kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
FLT4 | Fms-related tyrosine kinase 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FRK | Fyn-related Src family tyrosine kinase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Mixed |
FTL | Ferritin, light polypeptide | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
FXYD2 | FXYD domain containing ion transport regulator 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GAA | Glucosidase, alpha; acid | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
GABBR2 | Gamma-aminobutyric acid (GABA) B receptor, 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GABRA1 | Gamma-aminobutyric acid (GABA) A receptor, alpha 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GABRB2 | Gamma-aminobutyric acid (GABA) A receptor, beta 2 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GABRD | Gamma-aminobutyric acid (GABA) A receptor, delta | Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
GANAB | Glucosidase, alpha; neutral AB | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
GART | Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
GGPS1 | Geranylgeranyl diphosphate synthase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
GLRA2 | Glycine receptor, alpha 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
GRIA1 | Glutamate receptor, ionotropic, AMPA 1 | FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enriched |
GRIN2A | Glutamate receptor, ionotropic, N-methyl D-aspartate 2A | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enriched |
GSR | Glutathione reductase | Cancer-related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
GSS | Glutathione synthetase | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HBA1 | Hemoglobin, alpha 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
HBA2 | Hemoglobin, alpha 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |